The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
A. Goncalves
Honoraria - Bayer
F. Viret
No relevant relationships to disclose
E. François
No relevant relationships to disclose
L. Dahan
No relevant relationships to disclose
H. Perrier
No relevant relationships to disclose
R. Lamy
No relevant relationships to disclose
D. Re
No relevant relationships to disclose
R. Largillier
No relevant relationships to disclose
M. Gasmi
No relevant relationships to disclose
X. Tchiknavorian
No relevant relationships to disclose
O. Turrini
No relevant relationships to disclose
L. Moureau-Zabotto
No relevant relationships to disclose
J. Delpero
No relevant relationships to disclose
P. Viens
No relevant relationships to disclose